Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Value in Health

• Publication date

  2009-09-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/j.1524-4733.2009.00529.xPMID 19490556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

  2007cited by this paper
• Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.

  2007cited by this paper
• International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.

  2006cited by this paper
• Trends in community mortality due to coronary heart disease.

  2006cited by this paper
• A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone

  2005cited by this paper
• Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention.

  2005cited by this paper
• Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.

  2005cited by this paper
• Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

  2005cited by this paper
• Cost-Effectiveness of Eplerenone Compared With Placebo in Patients With Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure

  2005cited by this paper
• Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.

  2004cited by this paper
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

  2004cited by this paper
• Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis.

  2004cited by this paper
• Aspirin, clopidogrel, or both for secondary prevention of coronary disease.

  2003cited by this paper
• Aspirin, clopidogrel, or both for secondary prevention of coronary disease.

  2003cited by this paper
• Aspirin, clopidogrel, or both for secondary prevention of coronary disease.

  2003cited by this paper
• Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.

  2002cited by this paper
• Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

  2002cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods

  2002cited by this paper
• Health Databases in Saskatchewan

  2002cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.

  2000cited by this paper
• Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

  1997cited by this paper
• Cost-effectiveness of routine coronary angiography after acute myocardial infarction.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• The friction cost method for measuring indirect costs of disease.

  1995cited by this paper

• Early economic evaluation of single versus dual antiplatelet therapy after endovascular revascularisation for peripheral artery disease.

  2025cites this paper
• Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients

  2023cites this paper
• Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

  2022cites this paper
• The Future of Aspirin Therapy in Cardiovascular Disease.

  2021cites this paper
• Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

  2020influential citation
• Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction

  2020cites this paper
• Saving lives, saving limbs: tackling the global pandemic of peripheral arterial disease

  2019cites this paper
• Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review

  2018cites this paper
• Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta‐analysis

  2018cites this paper
• The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation

  2018cites this paper
• Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.

  2017cites this paper
• Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.

  2016cites this paper
• A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction

  2016cites this paper
• Cost-effectiveness of medical, endovascular and surgical management of peripheral vascular disease.

  2015cites this paper
• Dual platelet inhibition in cases of severe retrobulbar hemorrhage following retrobulbar and peribulbar anesthesia

  2015cites this paper
• Impact of Clopidogrel Plus Aspirin Versus Aspirin Alone on the Progression of Native Coronary Artery Disease After Bypass Surgery: Analysis From the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) Randomized Trial

  2014cites this paper
• Surgery for Coronary Artery DiseasE ( CASCADE ) Randomized Trial Coronary Artery Disease After Bypass Surgery : Analysis From the Clopidogrel After Impact of Clopidogrel Plus Aspirin Versus Aspirin Alone on the Progression of Native

  2014cites this paper
• Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?

  2014cites this paper
• The cost–effectiveness of strategies in coronary artery disease

  2014cites this paper
• Gender-stratified models to examine the relationship between financial hardship and self-reported oral health for older US men and women.

  2013cites this paper
• Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

  2012cites this paper
• Clopidogrel versus Aspirin in Patients with Atherothrombosis

  2012cites this paper
• Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.

  2012cites this paper
• Clinical and Economic Outcomes of Liberal Versus Selective Drug-Eluting Stent Use: Insights From Temporal Analysis of the Multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) Registry

  2011cites this paper
• Platelet Function in Patients with Diabetes Mellitus: From a Theoretical to a Practical Perspective

  2011cites this paper
• Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

  2011cites this paper
• Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

  2011cites this paper
• Clopidogrel (Plavix)

  2011cites this paper
• VIGNETTE Clopidogrel (Plavix)

  2011cites this paper
• Cost-effectiveness of oral antiplatelet agents—current and future perspectives

  2011cites this paper
• Transradial Approach for Coronary Angiography and Intervention - Ready for Prime Time?

  2010influential citation
• Sobre la prevención del ACV Del ACV no cardioembólico

  2010cites this paper
• Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI

  2010cites this paper
• Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses.

  2010cites this paper
• Analisi di costo-efficacia di prasugrel rispetto a clopidogrel nel trattamento di pazienti con sindrome coronarica acuta e intervento di angioplastica per via percutanea programmato

  2010cites this paper
• Current World Literature

  2002cites this paper